All In MedTech

FDA Clearance Tracker · P220012

Aurora EV-ICD System

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 19, 2026Latest source record: Oct 20, 2023 (this decision)Source: openFDAMethods & limitations

PMA

Decided

Oct 20, 2023

Approved

Time to decision

434 days

Received Aug 12, 2022. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P220012
Device name
Aurora EV-ICD System
Applicant location
Mounds View, MN
Received
Aug 12, 2022
Decided
Oct 20, 2023
Decision
Approved
Supplements
75 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code LWS

FDA's approval statement

As written in FDA's record.

the automated treatment of patients who have experienced, or are at significant risk of developing, life-threatening ventricular tachyarrhythmias through the delivery of antitachycardia pacing, cardioversion, and defibrillation therapies. Medical conditions that may indicate a patient for an EV-ICD for primary or secondary prevention of sudden cardiac death due to life-threatening ventricular tachyarrhythmias include: • Previous ventricular tachyarrhythmias• Coronary disease with left ventricular dysfunction• Cardiomyopathy• Inherited primary arrhythmia syndromes• Congenital heart diseaseNote: For patient-specific recommendations regarding indications for primary and secondary prevention of sudden cardiac death, refer to current clinical guidelines from the European Society of Cardiology (ESC), American Heart Association (AHA), American College of Cardiology (ACC), and Heart Rhythm Society (HRS).The Epsila EV™ MRI SureScan™ Model EV2401 extravascular lead is indicated for use in the anterior mediastinum for pacing therapies, cardioversion, and defibrillation when an extravascular implantable cardioverter defibrillator is indicated to treat patients who have experienced, or are at significant risk of developing, life-threatening ventricular tachyarrhythmias. The Epsila EV EAZ101 Sternal Tunneling Tool is indicated for use in the implant of a compatible anterior mediastinum defibrillation lead.The Epsila EV EAZ201 Transverse Tunneling Tool is indicated for use in the implant of a compatible anterior mediastinum defibrillation lead.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code LWS. The earliest in FDA's data is P830060, decided Oct 4, 1985.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Medtronic, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.